Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Only the generic-related statements and manufacturer/patent/availability content were provided; the supplied label excerpts only contain indication/limitation of use and abuse/misuse warnings, so most claims cannot be supported by the provided prescribing information.
Category Scores
Accurate Statements
Azstarys is a medication for Attention Deficit Hyperactivity Disorder (ADHD).
AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. (Section 1 INDICATIONS AND USAGE)
Unsupported Statements
Azstarys is not yet available in generic form.
No generic availability/patent/market-status information is present in the provided prescribing information excerpts.
Azstarys is still protected by patents that prevent generic versions from being manufactured and sold.
No patent-protection or legal/regulatory status information is present in the provided prescribing information excerpts.
The patent for Azstarys is set to expire in 2037.
No patent-expiration date information is present in the provided prescribing information excerpts.
A generic version of Azstarys is unlikely to be available until after 2037 unless earlier patent challenges are successful.
No generic availability/patent-challenge projections are present in the provided prescribing information excerpts.
If a patent for Azstarys were successfully challenged, it could lead to earlier availability of generic alternatives.
No discussion of patent challenges or impacts on generic availability is present in the provided prescribing information excerpts.
Azstarys is manufactured by Corium.
No manufacturer/sponsor/manufacturing company information is present in the provided prescribing information excerpts.
Corium is a subsidiary of Cognizant.
No corporate-structure information is present in the provided prescribing information excerpts.
Contradictions
Important Omissions
The AI-provided claims did not address the label’s pediatric limitation (not recommended in patients younger than 6 years due to higher plasma exposure and higher incidence of adverse reactions at the same dosage).
Importance:
Moderate
The AI-provided claims did not address the boxed warning content regarding abuse, misuse, and addiction risk (including increased risk with higher doses or unapproved methods such as snorting/injection) or the requirement to assess risk prior to prescribing and monitor during treatment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are legal/availability and corporate/manufacturing statements not directly tied to dosing/safety instructions in the provided label excerpts; however, the absence of the label’s safety warning content and pediatric limitation from the claims prevents evaluation of safety-critical label elements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims are unsupported by the provided prescribing information (patent/generic availability and corporate/manufacturer assertions) and key label safety/pediatric limitation content was omitted.
Suggested Improvement
Limit claims to the prescribing information excerpts provided (indication for ADHD patients 6 years and older; limitation not recommended <6 years; boxed warning on abuse/misuse/addiction and monitoring). Remove or qualify patent/generic availability and manufacturing/corporate statements unless supported by the full FDA label text.